Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 76

1.

Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy.

Morano F, Corallo S, Lonardi S, Raimondi A, Cremolini C, Rimassa L, Murialdo R, Zaniboni A, Sartore-Bianchi A, Tomasello G, Racca P, Clavarezza M, Adamo V, Perrone F, Gloghini A, Tamborini E, Busico A, Martinetti A, Palermo F, Loupakis F, Milione M, Fucà G, Di Bartolomeo M, de Braud F, Pietrantonio F.

J Clin Oncol. 2019 Sep 20:JCO1901254. doi: 10.1200/JCO.19.01254. [Epub ahead of print]

PMID:
31539295
2.

Use of Antibiotics and Risk of Cancer: A Systematic Review and Meta-Analysis of Observational Studies.

Petrelli F, Ghidini M, Ghidini A, Perego G, Cabiddu M, Khakoo S, Oggionni E, Abeni C, Hahne JC, Tomasello G, Zaniboni A.

Cancers (Basel). 2019 Aug 14;11(8). pii: E1174. doi: 10.3390/cancers11081174.

3.

Surgery or Locoregional Approaches for Hepatic Oligometastatic Pancreatic Cancer: Myth, Hope, or Reality?

Ghidini M, Petrillo A, Salati M, Khakoo S, Varricchio A, Tomasello G, Grossi F, Petrelli F.

Cancers (Basel). 2019 Aug 1;11(8). pii: E1095. doi: 10.3390/cancers11081095. Review.

4.

A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the 'BRAF BeCool' study.

Loupakis F, Intini R, Cremolini C, Orlandi A, Sartore-Bianchi A, Pietrantonio F, Pella N, Spallanzani A, Dell'Aquila E, Scartozzi M, De Luca E, Rimassa L, Formica V, Leone F, Calvetti L, Aprile G, Antonuzzo L, Urbano F, Prenen H, Negri F, Di Donato S, Buonandi P, Tomasello G, Avallone A, Zustovich F, Moretto R, Antoniotti C, Salvatore L, Calegari MA, Siena S, Morano F, Ongaro E, Cascinu S, Santini D, Ziranu P, Schirripa M, Buggin F, Prete AA, Depetris I, Biason P, Lonardi S, Zagonel V, Fassan M, Di Maio M.

Eur J Cancer. 2019 Sep;118:121-130. doi: 10.1016/j.ejca.2019.06.008. Epub 2019 Jul 19.

PMID:
31330487
5.

Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial.

Pietrantonio F, Morano F, Corallo S, Miceli R, Lonardi S, Raimondi A, Cremolini C, Rimassa L, Bergamo F, Sartore-Bianchi A, Tampellini M, Racca P, Clavarezza M, Berenato R, Caporale M, Antista M, Niger M, Smiroldo V, Murialdo R, Zaniboni A, Adamo V, Tomasello G, Giordano M, Petrelli F, Longarini R, Cinieri S, Falcone A, Zagonel V, Di Bartolomeo M, de Braud F.

JAMA Oncol. 2019 Jul 3. doi: 10.1001/jamaoncol.2019.1467. [Epub ahead of print]

6.

Major innovations and clinical applications of disodium-levofolinate: a review of available preclinical and clinical data.

Ratti M, Hahne JC, Toppo L, Castelli E, Petrelli F, Passalacqua R, Barni S, Tomasello G, Ghidini M.

Ther Adv Med Oncol. 2019 Jun 4;11:1758835919853954. doi: 10.1177/1758835919853954. eCollection 2019. Review.

7.

Risk of second primary tumors in GIST survivors: A systematic review and meta-analysis.

Petrelli F, Tomasello G, Barni S, Varricchio A, Costanzo A, Rampulla V, Cabiddu M, Turati L, Russo A, Seghezzi S, Passalacqua R, Ghidini M.

Surg Oncol. 2019 Jun;29:64-70. doi: 10.1016/j.suronc.2019.03.001. Epub 2019 Mar 6. Review.

PMID:
31196495
8.

Surrogate endpoints in immunotherapy trials for solid tumors.

Petrelli F, Ghidini M, Costanzo A, Rampulla V, Varricchio A, Tomasello G.

Ann Transl Med. 2019 Apr;7(7):154. doi: 10.21037/atm.2019.03.20. No abstract available.

9.

Outcome of head compared to body and tail pancreatic cancer: a systematic review and meta-analysis of 93 studies.

Tomasello G, Ghidini M, Costanzo A, Ghidini A, Russo A, Barni S, Passalacqua R, Petrelli F.

J Gastrointest Oncol. 2019 Apr;10(2):259-269. doi: 10.21037/jgo.2018.12.08.

10.

Timing of Adjuvant Chemotherapy and Survival in Colorectal, Gastric, and Pancreatic Cancer. A Systematic Review and Meta-Analysis.

Petrelli F, Zaniboni A, Ghidini A, Ghidini M, Turati L, Pizzo C, Ratti M, Libertini M, Tomasello G.

Cancers (Basel). 2019 Apr 17;11(4). pii: E550. doi: 10.3390/cancers11040550. Review.

11.

RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma.

Qin S, Finn RS, Kudo M, Meyer T, Vogel A, Ducreux M, Macarulla TM, Tomasello G, Boisserie F, Hou J, Li X, Song J, Zhu AX.

Future Oncol. 2019 Jun;15(16):1811-1822. doi: 10.2217/fon-2019-0097. Epub 2019 Apr 10.

12.

Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis.

Pusceddu S, Ghidini M, Torchio M, Corti F, Tomasello G, Niger M, Prinzi N, Nichetti F, Coinu A, Di Bartolomeo M, Cabiddu M, Passalacqua R, de Braud F, Petrelli F.

Cancers (Basel). 2019 Apr 5;11(4). pii: E484. doi: 10.3390/cancers11040484. Review.

13.

Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial.

Di Bartolomeo M, Niger M, Morano F, Corallo S, Antista M, Tamberi S, Lonardi S, Di Donato S, Berardi R, Scartozzi M, Cardellino GG, Di Costanzo F, Rimassa L, Luporini AG, Longarini R, Zaniboni A, Bertolini A, Tomasello G, Pinotti G, Scagliotti G, Tortora G, Bonetti A, Spallanzani A, Frassineti GL, Tassinari D, Giuliani F, Cinieri S, Maiello E, Verusio C, Bracarda S, Catalano V, Basso M, Ciuffreda L, De Vita F, Parra HS, Fornaro L, Caporale M, de Braud F, Pietrantonio F.

BMC Cancer. 2019 Mar 29;19(1):283. doi: 10.1186/s12885-019-5498-3.

14.

Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition.

Rimassa L, Bozzarelli S, Pietrantonio F, Cordio S, Lonardi S, Toppo L, Zaniboni A, Bordonaro R, Di Bartolomeo M, Tomasello G, Dadduzio V, Tronconi MC, Piombo C, Giordano L, Gloghini A, Di Tommaso L, Santoro A.

Clin Colorectal Cancer. 2019 Jun;18(2):125-132.e2. doi: 10.1016/j.clcc.2019.02.004. Epub 2019 Feb 14.

PMID:
30846365
15.

Adjuvant chemotherapy in patients with rectal cancer achieving pathologic complete response after neoadjuvant chemoradiation and surgery.

Tomasello G, Ghidini M, Petrelli F.

Eur J Cancer. 2019 Feb;108:97-99. doi: 10.1016/j.ejca.2018.12.014. Epub 2019 Jan 14. No abstract available.

PMID:
30648634
16.

Biliary tract cancer: current challenges and future prospects.

Ghidini M, Pizzo C, Botticelli A, Hahne JC, Passalacqua R, Tomasello G, Petrelli F.

Cancer Manag Res. 2018 Dec 28;11:379-388. doi: 10.2147/CMAR.S157156. eCollection 2019. Review.

17.

Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study.

Fanotto V, Fornaro L, Bordonaro R, Rosati G, Rimassa L, Di Donato S, Santini D, Tomasello G, Leone F, Silvestris N, Stragliotto S, Scartozzi M, Giampieri R, Nichetti F, Antonuzzo L, Cinieri S, Avallone A, Pellegrino A, Melisi D, Vasile E, Gerratana L, Aprile G.

J Geriatr Oncol. 2019 Jul;10(4):591-597. doi: 10.1016/j.jgo.2018.11.009. Epub 2018 Dec 11.

PMID:
30551958
18.

Addition of radiotherapy to the primary tumour in oligometastatic NSCLC: A systematic review and meta-analysis.

Petrelli F, Ghidini A, Cabiddu M, Tomasello G, De Stefani A, Bruschieri L, Vitali E, Ghilardi M, Borgonovo K, Barni S, Trevisan F.

Lung Cancer. 2018 Dec;126:194-200. doi: 10.1016/j.lungcan.2018.11.017. Epub 2018 Nov 13. Review.

PMID:
30527187
19.

Neoadjuvant chemoradiotherapy or chemotherapy for gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis.

Petrelli F, Ghidini M, Barni S, Sgroi G, Passalacqua R, Tomasello G.

Gastric Cancer. 2019 Mar;22(2):245-254. doi: 10.1007/s10120-018-0901-3. Epub 2018 Nov 27.

PMID:
30483986
20.

Estimating Survival Probabilities of Advanced Gastric Cancer Patients in the Second-Line Setting: The Gastric Life Nomogram.

Pietrantonio F, Barretta F, Fanotto V, Park SH, Morano F, Fucà G, Niger M, Prisciandaro M, Silvestris N, Bergamo F, Fornaro L, Bordonaro R, Rimassa L, Santini D, Tomasello G, Antonuzzo L, Noventa S, Avallone A, Leone F, Faloppi L, Di Donato S, de Braud F, Lee J, De Vita F, Di Bartolomeo M, Miceli R, Aprile G.

Oncology. 2018;95(6):344-352. doi: 10.1159/000491753. Epub 2018 Aug 21.

PMID:
30130791

Supplemental Content

Loading ...
Support Center